Kevin Charles Gorman - 13 Feb 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Director
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
13 Feb 2026
Net transactions value
-$5,002,657
Form type
4
Filing time
17 Feb 2026, 17:44:32 UTC
Previous filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GORMAN KEVIN CHARLES Director 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 17 Feb 2026 0001201096

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $0 +5,604 +1.1% $0.000000 522,497 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $375,339 -3,024 -0.58% $124.12 519,473 13 Feb 2026 Direct F1
transaction NBIX Common Stock Options Exercise $0 +5,377 +1% $0.000000 524,850 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $360,072 -2,901 -0.55% $124.12 521,949 13 Feb 2026 Direct F1
transaction NBIX Common Stock Award $0 +63,724 +12% $0.000000 585,673 13 Feb 2026 Direct F2
transaction NBIX Common Stock Tax liability $4,267,246 -34,380 -5.9% $124.12 551,293 13 Feb 2026 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Restricted Stock Unit Options Exercise $0 -5,604 -33% $0.000000 11,208 13 Feb 2026 Common Stock 5,604 Direct F4, F5
transaction NBIX Restricted Stock Unit Options Exercise $0 -5,377 -50% $0.000000 5,377 13 Feb 2026 Common Stock 5,377 Direct F4, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
F2 On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
F3 551,293 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.
F4 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5 This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 5,603 shares on February 13, 2025, vested as to 5,604 shares on February 13, 2026, and will vest as to 5,604 shares on February 13, 2027, and 5,604 shares on February 13, 2028, subject to the terms and conditions of the award.
F6 This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 5,376 shares on February 13, 2024, vested as to 5,376 shares on February 13, 2025, vested as to 5,377 shares on February 13, 2026, and will vest as to 5,377 shares on February 13, 2027, subject to the terms and conditions of the award.